2020 Fiscal Year Final Research Report
The role of SALL4 in myelodysplastic syndrome
| Project/Area Number |
17K09930
|
|---|
| Research Category |
Grant-in-Aid for Scientific Research (C)
|
| Allocation Type | Multi-year Fund |
|---|
| Section | 一般 |
|---|
| Research Field |
Hematology
|
|---|
| Research Institution | Kumamoto University |
|---|
Principal Investigator |
|
|---|
| Project Period (FY) |
2017-04-01 – 2021-03-31
|
| Keywords | 骨髄異形成症候群 / SALL4 |
|---|
| Outline of Final Research Achievements |
Myelodysplastic syndrome (MDS) is a group of heterogeneous diseases characterized by cytologic dysplasia and refractory cytopenias as a result of ineffective hematopoiesis. Some MDS cases progress to acute myeloid leukemia (AML) with poor prognosis and short survival time. We have reported that oncofetal protein SALL4 can be used as a prognostic biomarker in MDS disease.In this study, we evaluated the expression of SALL4 using single-cell mass cytometry (CyTOF) and Nanostring nCounter. SALL4 was expressed in various MDS BM cells. P53, which is an adverse prognostic marker, positive cells were chiefly seen in SALL4 positive CD34+ cells, erythroid cells and part of myeloid cells. These results indicated that SALL4 could be a candidate of target for MDS therapy.
|
| Free Research Field |
血液内科
|
| Academic Significance and Societal Importance of the Research Achievements |
骨髄異形成症候群（MDS）は、未だ難治性血液疾患であり、治療法の開発が急務な疾患です、今回、私達は、さまざまな腫瘍に高発現を認めるSALL4に着目し、マスサイトメトリーやナノストリングの手法を用いて解析を行ないました。正常骨髄と比べ、MDS骨髄においては、造血幹細胞を含むさまざな細胞でタンパクレベルでのSALL4の高発現を認めました。また、SALL4の高発現細胞の一部は、予後不良因子であるP53も高発現していました。SALL4陽性細胞は、治療のターゲットとなる可能性が示唆され、今後、SALL4の機能解析をさらに進めるとともにSALL4をターゲットとした治療法の開発を進めたいと考えました。
|
